Japanese journal of clinical oncology最新文献

{"title":"Nationwide retrospective survey on healthcare professionals' perceptions of suicide-related behaviors among people with head and neck cancer in Japan.","authors":"Kohtaro Eguchi, Seiichi Yoshimoto, Maiko Fujimori, Yosuke Uchitomi","doi":"10.1093/jjco/hyaf125","DOIUrl":"https://doi.org/10.1093/jjco/hyaf125","url":null,"abstract":"<p><strong>Objective: </strong>To investigate healthcare professionals' perceptions of suicide-related behaviors among people with head and neck cancers in Japan.</p><p><strong>Methods: </strong>A two-phase, multicenter retrospective study was conducted. First, head and neck cancer specialists completed a survey on their experience with suicide-related behaviors and institutional prevention efforts. Second, a medical record review explored associations between suicide-related behaviors and treatment factors.</p><p><strong>Results: </strong>There were 152 respondents, of whom 82 (53.9%) had encountered suicide-related behaviors, and 69 (45.4%) had experienced patient suicides. A total of 110 cases of suicide were reported. Only 4.6% of respondents had attended lectures on preventing suicide, although 37.5% had implemented preventive measures. Overall, 27 cases were analyzed, including 18 suicides, and nine attempts. The majority of these involved men who were either smokers or drinkers. Behaviors often occurred when people were post-treatment without any recurrence. Common preceding factors were eating difficulties, speech impairment, and psychological decline.</p><p><strong>Conclusions: </strong>Suicide risk among people with head and neck cancer extends well beyond diagnosis and remains under-addressed. Increased awareness and education among healthcare professionals, and provision of multidisciplinary support, are essential for comprehensive prevention.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A questionnaire-based cross-sectional study on neuropathic pain in patients with cancer in Japan.","authors":"Saori Hashiguchi, Hiroshi Takahashi, Shuhei Yamamoto, Haruhiko Seki, Yaoki Sonohara, Yuko Tanabe","doi":"10.1093/jjco/hyaf116","DOIUrl":"https://doi.org/10.1093/jjco/hyaf116","url":null,"abstract":"<p><strong>Background: </strong>Some patients with cancer experience cancer-related neuropathic pain. This study investigated the prevalence of possible neuropathic pain in patients with cancer.</p><p><strong>Methods: </strong>This observational, cross-sectional, questionnaire-based study recruited adult participants with stage ≥II cancer in Japan between June and November 2024. The primary endpoint was the proportion of participants with suspected neuropathic pain (Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale [S-LANSS] score ≥ 12 points). Secondary endpoints included pain scores (11-point numeric rating scale [NRS]), communication with healthcare professionals, impact on daily activities, and quality of life (QoL) per the EQ-5D-5L.</p><p><strong>Results: </strong>Responses from 713 participants were analyzed. Of those, 230 participants (32.3%) reported cancer-related pain and 53 (7.4%) had suspected neuropathic pain. Among participants with suspected neuropathic pain, the mean ± standard deviation (SD) pain intensity (NRS) was 5.1 ± 2.7. Over one-third of participants (37.7% [20/53]) with suspected neuropathic pain reported that no healthcare provider had asked about cancer pain before they sought a consultation, 60.4% (32/53) wished their healthcare provider had noticed their pain sooner, 69.8% (37/53) could no longer perform some daily activities due to cancer pain, and 98.1% (52/53) thought their pain needed to be adequately treated for them to live their life going forward. QoL was lower among participants with suspected neuropathic pain versus the overall population (EQ-5D-L mean ± SD: 0.6065 ± 0.2518 vs 0.8204 ± 0.1788).</p><p><strong>Conclusions: </strong>These findings suggest that pain assessment earlier in the cancer treatment process than standard may improve pain management for patients with cancer.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups.","authors":"","doi":"10.1093/jjco/hyaf129","DOIUrl":"https://doi.org/10.1093/jjco/hyaf129","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseases.","authors":"Daisuke Minami, Nagio Takigawa, Tatsuyuki Kawahara, Akichika Nagano, Yasuhiro Nakajima, Nobuaki Ochi, Hiromichi Yamane, Arihiko Kanehiro","doi":"10.1093/jjco/hyaf124","DOIUrl":"https://doi.org/10.1093/jjco/hyaf124","url":null,"abstract":"<p><strong>Background: </strong>Recently, a transbronchial needle biopsy (TBNB) method using a three-plane symmetric Acquire needle with Franseen geometry was developed to improve diagnostic yield. This study describes our experience with Endobronchial ultrasound (EBUS)-TBNB for pulmonary and mediastinal diseases.</p><p><strong>Methods: </strong>A retrospective review was conducted involving 37 patients who underwent EBUS-TBNB with an Acquire 22G needle between July 2021 and September 2024. Enlarged lymph nodes were sampled, and medical records were analyzed to evaluate diagnostic outcomes, including histological core tissue acquisition, programmed death-ligand 1 (PD-L1) expression testing, and next-generation sequencing (NGS).</p><p><strong>Results: </strong>We sampled a total of 48 lymph nodes (26 subcarinal [#7], 12 right lower paratracheal [#4R], and 10 right hilar [#11]) with a median longest diameter of 23.1 mm (range, 9.3-44.6 mm). Definitive diagnoses were achieved in 36 patients, including 25 cases of lung cancer, one large-cell neuroendocrine carcinoma, one renal cell carcinoma, five cases of sarcoidosis, and four cases of unspecified lymphadenopathy. The overall diagnostic yield was 97.3% (95% confidence interval: 85.8%-99.5%). Both PD-L1 expression testing and NGS were successfully performed in all lung adenocarcinoma cases (nine using the Oncomine Dx Target Test and four using the AmoyDx Pan Lung Cancer polymerase chain reaction (PCR) Panel). Histological samples were successfully obtained from 35 patients, whereas only two cases of lung squamous cell carcinoma were cytologically diagnosed due to necrotic and calcified samples. The nucleic acid yield from a single puncture was sufficient for analysis using the Lung Cancer Compact Panel.</p><p><strong>Conclusions: </strong>EBUS-TBNB demonstrated high efficacy for diagnosing lung cancer, including PD-L1 testing and NGS, and for obtaining histological core tissue.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-organ examination of hematologic toxicities from immune checkpoint inhibitors: insights from real-world data.","authors":"Sayako Yuda, Yuma Tada, Yasuhiro Shingai, Hidenori Kasahara, Shigeo Fuji, Hiroaki Masaie, Takafumi Yokota, Jun Ishikawa","doi":"10.1093/jjco/hyaf118","DOIUrl":"https://doi.org/10.1093/jjco/hyaf118","url":null,"abstract":"<p><strong>Objective: </strong>Immune checkpoint inhibitors (ICPis) are widely used clinically to improve the prognosis of various cancers. However, little is known about their hematologic immune-related adverse events (irAEs). This study aimed to comprehensively investigate the incidence and clinical characteristics of irAEs induced by ICPis through a cross-organ research approach.</p><p><strong>Methods: </strong>Patients who received at least one ICPi dose at the Osaka International Cancer Institute between January 2014 and September 2021 were reviewed, irrespective of their tumor type. We analyzed the cumulative incidence of hematological irAEs and investigated the clinical course of patients who underwent bone marrow examination owing to suspected hematological irAEs.</p><p><strong>Results: </strong>During the study period, 1500 patients in total received ICPis. Based on clinical data and the histopathological evaluation of bone marrow samples, we identified seven cases of hematologic irAEs (four of immune thrombocytopenia, two of hemophagocytic lymphohistiocytosis, and one of agranulocytosis). Additionally, we observed six cases of primary hematologic disease, four of bone marrow findings consistent with cytopenia and subsequent recovery secondary to infections or cytotoxic agents, two of bone marrow involvement by primary cancer, and one of an unknown cause. With the median follow-up of 297 days (0-2087 days), the cumulative incidence rates of hematologic irAEs at 90 days and 1 year were 0.1% (95% CI, 0.0-0.4) and 0.4% (95% CI, 0.2-1.0), respectively. None of the patients with hematological irAEs died.</p><p><strong>Conclusion: </strong>Severe hematological irAEs are rare but can be life-threatening. When hematological abnormalities are detected during ICPi therapy, it is important to explore the possibility of irAEs, including bone marrow abnormalities.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional disparities in lymphedema treatment and access to complex decongestive therapy: a nationwide survey in Japan.","authors":"Mariko Masujima, Shinsuke Akita, Makiko Tazaki, Akane Tsujimoto, Ryoko Katagiri, Chikao Yasuda, Tetsuya Tsuji","doi":"10.1093/jjco/hyaf120","DOIUrl":"https://doi.org/10.1093/jjco/hyaf120","url":null,"abstract":"<p><strong>Background: </strong>Lymphedema has a significant impact on patient quality of life. However, it remains unclear whether the provision of lymphedema treatment in Japan is uniform across regions. This study aimed to clarify the current situation regarding lymphedema treatment with emphasis on complex decongestive therapies (CDT) availability and implementation in Japan.</p><p><strong>Methods: </strong>A nationwide web-based survey was conducted. Respondents included healthcare professionals from designated cancer care hospitals and other medical institutions treating lymphedema in Japan. The distribution of variables, including the implementation of lymphedema treatment, was compared between designated cancer care hospitals and other facilities using the chi-square test. Japan was divided into nine regions to compare and analyze access to medical institutions providing CDT for lymphedema on both inpatient and outpatient bases.</p><p><strong>Results: </strong>Of the 372 facility responses analyzed, ˃95% reported treating secondary lymphedema of the extremities, whereas ˂30% treated head and neck lymphedema. The number of CDT inpatients per 100 000 people in the region with the lowest patient volume was approximately 2% of that in the region with the highest volume. Similarly, the number of CDT outpatients per 100 000 people in the lowest-volume region was one-third of that in the highest-volume region. There was no significant correlation between facilities with high outpatient numbers and those with low outpatient numbers (ρ =0.57, P-value = 0.11).</p><p><strong>Conclusion: </strong>Eliminating regional disparities in access to lymphedema treatment facilities, particularly for inpatient CDT, would improve quality of life and enable patients to manage the condition regardless of where they live.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcome of patients with soft tissue sarcoma after bone metastases: Tokai musculoskeletal oncology consortium study.","authors":"Tomohito Hagi, Tomoki Nakamura, Satoshi Tsukushi, Hiroshi Koike, Hiroaki Kimura, Akihito Nagano, Kozo Hosono, Yoji Shido, Eiji Kozawa, Katsuhisa Kawanami, Kunihiro Asanuma, Yumi Matsuyama, Masahiro Hasegawa, Yoshihiro Nishida","doi":"10.1093/jjco/hyaf121","DOIUrl":"https://doi.org/10.1093/jjco/hyaf121","url":null,"abstract":"<p><strong>Background: </strong>Soft tissue sarcomas (STSs) are a diverse group of rare malignant tumors accounting for <1% of all human tumors. Almost 50% of patients with STS develop metastatic disease, mainly within 3 years of initial diagnosis. Lung metastasis occurs in 20%-30% of STS cases, while bone metastasis is rare.</p><p><strong>Patients and methods: </strong>We investigated tumor characteristics and clinical outcomes in 59 patients with STS who developed bone metastases.</p><p><strong>Results: </strong>A total of 21 patients had solitary bone metastasis: two in the extremity, 11 in the vertebral body, and eight in the trunk. Around 38 patients had multiple bone metastases: 18 with extremity bone involvement and 20 with no extremity bone involvement. Fourteen patients developed complicated bone metastases with distant extrapulmonary metastases. Seven patients had no distant metastases other than bone; that is, the bone was the first distant metastasis. The 5-year disease-specific survival (DSS) rate after primary treatment was 45.1%. The median 5-year DSS after bone metastasis was 28.1 months. The 5-year DSS rate was 55.6% in nine patients who underwent radical local treatment for solitary bone metastases. The 5-year DSS rate was 14.7% in 50 patients who did not undergo local radical treatment for bone metastases, with a significant correlation.</p><p><strong>Conclusion: </strong>Patients with bone metastases from STS had a relatively good prognosis after bone metastases. Solitary bone metastases can be aggressively treated. Although nearly half of the patients received bone-modifying agents, the effectiveness of these therapeutics warrants further investigation.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biliary stenting implantation with 125I seed strand followed by chemotherapy plus PD-1 inhibitor in cholangiocarcinoma with malignant obstructive jaundice: a retrospective comparative study.","authors":"Tianhua Yue, Wenlong Gu, You Lu","doi":"10.1093/jjco/hyaf123","DOIUrl":"https://doi.org/10.1093/jjco/hyaf123","url":null,"abstract":"<p><strong>Background: </strong>Owing to the nonspecific symptoms in early stage and the propensity for secondary obstructive jaundice, cholangiocarcinoma (CCA) is frequently diagnosed at an advanced stage, thereby missing the optimal window for surgical intervention. The aim of this study was to evaluate the efficacy and safety of biliary stenting implantation with 125I seed strand (SI) plus chemotherapy with PD-1inhibitor for patients with CCA and malignant obstructive jaundice (MOJ).</p><p><strong>Methods: </strong>Between January 2015 and December 2023, 88 patients diagnosed with CCA and MOJ were enrolled for this retrospective study. Then, 36 patients (observation group) received SI plus chemotherapy with PD-1inhibitor, whereas 52 patients (control group) received biliary stenting implantation plus chemotherapy. The response to therapy and adverse effect were compared between both groups. The data of stent patency time, progression-free survival (PFS) and overall survival (OS) obtained through clinical follow-up, were performed using the Kaplan-Meier method and analysed with the log-rank test. Prognostic risk factors were evaluated using Cox regression analysis.</p><p><strong>Results: </strong>After the 6-month follow-up, the DCR (86.11% vs 67.31%) was statistically different (P = 0.045), while ORR (33.33% vs 23.08%) not (P = 0.288) between both groups. There were no serious interventional treatment-related adverse events and the differences of severe toxicities of chemotherapy between both groups were not statistically significant (P > 0.05). The median stent patency time, PFS and OS were 300 days (95%CI 260-330) vs 215 days (95%CI 194-240), 360 days (95%CI 260-372) vs 230 days (95%CI 200-248) and 420 days (95%CI 330-452) vs 309 days (95%CI 252-340) between both groups, respectively and the differences between both groups were statistically significant (P < 0.05). Staging of CCA and subsequent therapy method were independent risk factors that affected the prognosis for survival.</p><p><strong>Conclusions: </strong>SI plus chemotherapy with PD-1inhibitor is an effective and safe therapy and shows promising results compared to biliary stenting implantation plus chemotherapy for CCA patients with MOJ.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14 mg) plus pembrolizumab for metastatic renal cell carcinoma.","authors":"Tomokazu Sazuka, Kentaro Murakami, Hidetaka Nihei, Yuki Iida, Kosuke Mikami, Sangjon Pae, Shinpei Saito, Keisuke Ando, Manato Kanesaka, Kodai Sato, Yasutaka Yamada, Yusuke Imamura, Shinichi Sakamoto, Tomohiko Ichikawa","doi":"10.1093/jjco/hyaf122","DOIUrl":"https://doi.org/10.1093/jjco/hyaf122","url":null,"abstract":"<p><strong>Objective: </strong>In the CLEAR trials, the starting dose of lenvatinib in lenvatinib+pembrolizumab (L + P) was set at 20 mg for renal cell carcinoma (RCC). The incidence of adverse events is not low with L + P compared with other combination immunotherapies. There have been no reports of initiating treatment at 14 mg lenvatinib in (L + P) combination treatment for metastatic RCC (mRCC).</p><p><strong>Methods: </strong>Patients who initiated L + P for mRCC between January 2022 and 2024 in our institution were included. Clinical data were collected retrospectively. Patients' backgrounds and adverse events were summarized, and the maximum tumor shrinkage rate and treatment progress were analyzed.</p><p><strong>Results: </strong>Eleven patients were enrolled in this study; median age: 69 years, median body weight: 63.0 kg. Two patients were female. The International Metastatic Renal Cell Database Consortium risk score was favorable in two cases, intermediate in six cases, and poor in three cases. Adverse events led to drug interruption or discontinuation of treatment in four cases, 2 months after initiating L + P. Partial response was achieved in 10 (91%) cases; stable disease was achieved in only 1 case. Almost all patients experienced some type of adverse event (AE). Only one patient discontinued treatment due to AEs.</p><p><strong>Conclusions: </strong>Although management of AEs was essential, early drug interruption was less frequent in our study compared with the CLEAR trial Japanese cohort. The response of a reduced starting dose of 14 mg lenvatinib for mRCC was almost the same as that in the CLEAR trial.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on the management of BCOR::CCNB3 sarcoma.","authors":"Jungo Imanishi, Kenji Sato, Yoshinao Kikuchi, Asako Yamamoto, Shiori Watabe, Taisuke Matsuyama, Chiaki Sato, Hiroshi Kobayashi, Hirotaka Kawano","doi":"10.1093/jjco/hyaf111","DOIUrl":"https://doi.org/10.1093/jjco/hyaf111","url":null,"abstract":"<p><p>BCOR::CCNB3 sarcoma is a rare sarcoma defined by the BCOR::CCNB3 fusion gene. It predominantly affects males under 20, with a slight predominance of bone origin. Initially grouped as 'Ewing-like,' it is now a distinct entity, a major part of 'sarcoma with BCOR genetic alterations.' Incidence is low, estimated at under 10 annual cases in Japan. Radiologically, it can mimic other high-grade sarcomas, with variable lytic or sclerotic bone lesions and nonspecific soft tissue findings. By contrast, it sometimes appears well-defined and benign-like. Pathologically, the detection of BCOR::CCNB3 fusion is key to diagnosis. Histology varies from small round cells to spindle cells, showing CD99, BCOR, Cyclin D1, and SATB2 positivity, with CCNB3 differentiating it from BCOR-ITD. Molecular testing confirms the diagnosis. Treatment involves wide resection and chemotherapy, with the Ewing sarcoma protocol often chosen. Approximately 20% are metastatic at diagnosis, and local recurrence after surgery occurs in as high as ⁓20% of BCOR::CCNB3 sarcomas. The relatively high local recurrence rate is probably because of the infiltrative growth. Complete response to neoadjuvant chemotherapy may indicate a better prognosis. Less frequent metastasis at diagnosis indicates that this sarcoma is less aggressive than Ewing sarcoma. Five-year overall survival is ⁓75%, but the prognosis of non-resectable or metastatic cases is worse. Further research is crucial for tailored treatment. Due to the tumor's super-rarity, collaborative, multi-institutional studies are essential, allowing for robust clinical trials and outcome analyses. Long-term follow-up studies are also necessary to assess late effects and survival.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}